The anti-inflammatory and antioxidant effects of astaxanthin as an adjunctive therapy in community-acquired pneumonia: a randomized controlled trial
BackgroundCommunity-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide, particularly in low- and middle-income countries. Oxidative stress and excessive inflammation contribute significantly to disease progression and severity. Astaxanthin (ASX), a potent antioxidant an...
Saved in:
| Main Authors: | Fatma Makram Youssef, Hayam Ateyya, Amir Eskander Hanna Samy, Eman Mohamed Elmokadem |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1621308/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cytokine profile in community-acquired pneumonia in children
by: N. V. Iziurova, et al.
Published: (2022-11-01) -
Novelties in the treatment of community-acquired and hospital-acquired pneumonia
by: Matteo Bassetti, et al.
Published: (2025-04-01) -
1H NMR to assess bioaccessibility and stability of designed astaxanthin nanoemulsions
by: S. Bautista-Hernández, et al.
Published: (2025-12-01) -
Comparison of the effects and mechanisms of astaxanthin, astaxanthin esters and astacene on high-fat diet-induced NAFLD
by: Chunhao Gao, et al.
Published: (2025-10-01) -
ADJUNCTIVE THERAPY OF COMMUNITY-ACKUIRED PNEUMONIA: NECESSITY AND SUFFICIENCY
by: L. V. Savchenkova, et al.
Published: (2016-12-01)